欧洲硬皮病观察性研究中早期弥漫性系统性硬化症皮肤评分变化的模式与预测因素
基于欧洲硬皮病观察性研究326例早期弥漫性皮肤型系统性硬化症患者,每3个月记录改良Rodnan皮肤评分(mRSS),66例(22.5%)在12个月(±3个月)内进展。进展者病程更短、mRSS更低;抗RNA聚合酶III阳性亚组皮肤评分最高且达峰最早。建立两个预测模型,加入Pol3阳性变量后准确度71%、AUC 0.711、PPV 41%。
要点
- 326例中66例(22.5%)12个月内mRSS进展,227例(77.5%)未进展,33例因数据不足无法评估。
- 进展者病程中位8.1 vs 12.6个月(P=0.001),mRSS中位19 vs 21单位(P=0.030)。
- 加入Pol3阳性变量后模型准确度71%、AUC 0.711、PPV 41%,优于基础模型。
核心结论
- 推导出两个用于预测皮肤增厚进展的模型,可用于临床实践和随机对照试验(RCT)的队列富集。
- 这些模型将为未来数年计划开展的众多dcSSc临床试验提供招募信息。
研究设计与样本
- 欧洲硬皮病观察性研究,每3个月记录326例早期弥漫性皮肤型系统性硬化症(dcSSc)患者的改良Rodnan皮肤评分(mRSS)。
- 进展者定义为12个月(±3个月)内mRSS增加5单位且增加25%。
- 拟合逻辑回归模型预测进展,并用受试者工作特征(ROC)曲线基于曲线下面积(AUC)、准确度和阳性预测值(PPV)进行比较。
- 试验注册号NCT02339441。
主要发现
- 66例(22.5%)进展,227例(77.5%)未进展,33例因数据不足无法评估状态。
- 进展者病程中位8.1 vs 12.6个月(P=0.001),mRSS中位19 vs 21单位(P=0.030),均低于非进展者。
- 抗RNA聚合酶III(Pol3+)亚组(n=50)皮肤评分最高且达峰最早。
- 第一个预测模型(含mRSS、皮肤增厚病程及二者交互作用)准确度60.9%、AUC 0.666、PPV 33.8%。
- 加入Pol3阳性变量后模型准确度71%、AUC 0.711、PPV 41%。
关键数值与推荐
- 进展定义:12个月(±3个月)内mRSS增加5单位且增加25%。
- 基础模型准确度60.9%、AUC 0.666、PPV 33.8%;加入Pol3阳性后准确度71%、AUC 0.711、PPV 41%。
临床怎么用
- 原文结论指出两个预测模型可用于临床实践和RCT队列富集,并将为未来dcSSc临床试验招募提供信息。
局限性
- 33例因数据不足无法评估进展状态。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Our aim was to use the opportunity provided by the European Scleroderma Observational Study to (1) identify and describe those patients with early diffuse cutaneous systemic sclerosis (dcSSc) with progressive skin thickness, and (2) derive prediction models for progression over 12 months, to inform future randomised controlled trials (RCTs). METHODS: The modified Rodnan skin score (mRSS) was recorded every 3 months in 326 patients. 'Progressors' were defined as those experiencing a 5-unit and 25% increase in mRSS score over 12 months (±3 months). Logistic models were fitted to predict progression and, using receiver operating characteristic (ROC) curves, were compared on the basis of the area under curve (AUC), accuracy and positive predictive value (PPV). RESULTS: 66 patients (22.5%) progressed, 227 (77.5%) did not (33 could not have their status assessed due to insufficient data). Progressors had shorter disease duration (median 8.1 vs 12.6 months, P=0.001) and lower mRSS (median 19 vs 21 units, P=0.030) than non-progressors. Skin score was highest, and peaked earliest, in the anti-RNA polymerase III (Pol3+) subgroup (n=50). A first predictive model (including mRSS, duration of skin thickening and their interaction) had an accuracy of 60.9%, AUC of 0.666 and PPV of 33.8%. By adding a variable for Pol3 positivity, the model reached an accuracy of 71%, AUC of 0.711 and PPV of 41%. CONCLUSIONS: Two prediction models for progressive skin thickening were derived, for use both in clinical practice and for cohort enrichment in RCTs. These models will inform recruitment into the many clinical trials of dcSSc projected for the coming years. TRIAL REGISTRATION NUMBER: NCT02339441.
引用
- Herrick AL, Peytrignet S, Lunt M, et al. Patterns and predictors of skin score change in early diffuse systemic sclerosis from the European Scleroderma Observational Study. Ann Rheum Dis. 2018. PMID: 29306872. doi:10.1136/annrheumdis-2017-211912
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。